Evidence map›Paper›PMID 26365387›Full record

ArticleThe Journal of allergy and clinical immunology2016

Protein microarrays identify disease-specific anti-cytokine autoantibody profiles in the landscape of immunodeficiency.

Jacob M Rosenberg, Jordan V Price, Gabriela Barcenas-Morales, Lourdes Ceron-Gutierrez, Sophie Davies, Dinakantha S Kumararatne, Rainer Döffinger, Paul J Utz

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in The Journal of allergy and clinical immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 21 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. IL-6-specific autoantibodies among APECED and thymoma patients.Immunity, inflammation and disease · 2016
    Article
  11. Review
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Jacob M RosenbergDepartment of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, Calif. Electronic address: JakeRos@stanford.edu.
Jordan V PriceDepartment of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, Calif.
Gabriela Barcenas-MoralesDepartment of Clinical Biochemistry and Immunology, Addenbrooke's Hospital, Cambridge, United Kingdom; Laboratorio de Inmunologia, UNAM, FES-Cuautitlan, Cuautitlán Izcalli, Mexico.
Lourdes Ceron-GutierrezDepartment of Clinical Biochemistry and Immunology, Addenbrooke's Hospital, Cambridge, United Kingdom.
Sophie DaviesDepartment of Clinical Biochemistry and Immunology, Addenbrooke's Hospital, Cambridge, United Kingdom.
Dinakantha S KumararatneDepartment of Clinical Biochemistry and Immunology, Addenbrooke's Hospital, Cambridge, United Kingdom.
Rainer DöffingerDepartment of Clinical Biochemistry and Immunology, Addenbrooke's Hospital, Cambridge, United Kingdom; National Institute for Health Research (NIHR), Cambridge Biomedical Research Centre, Cambridge, United Kingdom.
Paul J UtzDepartment of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, Calif; Institute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford, Calif. Electronic address: PJUtz@stanford.edu.
Addenbrooke's Hospital · GBStanford University · US

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007365 · NIGMS · STANFORD UNIVERSITY · PI CHUA, KATRIN F · 1985 to 2021
$33.8M
Autoimmunity Center of Excellence Clinical Research ProgramUM1AI110498 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WOFSY, DAVID · 2014 to 2019
$31.4M
Vaccination and infection: indicators of immunological health and responsivenessU19AI090019 · NIAID · STANFORD UNIVERSITY · PI DAVIS, MARK MORRIS · 2010 to 2015
$17.3M
Tissue Acquisition Research GroupUM2AR067678 · NIAMS · STANFORD UNIVERSITY · PI HOLERS, VERNON MICHAEL, UTZ, PAUL JOSEPH · 2014 to 2020
$8.2M
Strategies for Prevention of AutoimmunityU19DK061934 · NIDDK · STANFORD UNIVERSITY · PI FATHMAN, CHARLES GARRISON · 2001 to 2005
$4.4M
Ultra-Fast Epigenomic Maps for Monitoring AutoimmunityU19AI110491 · NIAID · STANFORD UNIVERSITY · PI UTZ, PAUL JOSEPH · 2014 to 2018
$3.6M
Stanford Technology Accelerating Medicines Partnership CenterUH2AR067676 · NIAMS · STANFORD UNIVERSITY · PI ROBINSON, WILLIAM H, UTZ, PAUL JOSEPH · 2014 to 2020
$2.6M
Multiplex Autoantibody Profiling in SLER01AI051614 · NIAID · STANFORD UNIVERSITY · PI UTZ, PAUL JOSEPH · 2003 to 2007
$1.9M
NHLBI NIH HHS N01-HV-00242NIAID NIH HHS 1 U19-AI090019NIAID NIH HHS 1 U19-AI110491NIAID NIH HHS 1 UM1AI110498NIAID NIH HHS R01 AI051614NIAID NIH HHS U19 AI090019NIAID NIH HHS U19 AI110491NIAMS NIH HHS 1 UH2 AR067676NIAMS NIH HHS 1 UM2 AR067678NIAMS NIH HHS UH2 AR067676NIAMS NIH HHS UM2 AR067678NIDDK NIH HHS U19 DK061934NIGMS NIH HHS T32 GM007365NIGMS NIH HHS T32GM007365PHS HHS HSN268201000034C
6 · The paper itself

Abstract

backgroundAnti-cytokine autoantibodies (ACAAs) are pathogenic in a handful of rare immunodeficiencies. However, the prevalence and significance of other ACAAs across immunodeficiencies have not yet been described.

objectiveWe profiled ACAAs in a diverse cohort of serum samples from patients with immunodeficiency and assessed the sensitivity and specificity of protein microarrays for ACAA identification and discovery.

methodsHighly multiplexed protein microarrays were designed and fabricated. Blinded serum samples from a cohort of 58 immunodeficiency patients and healthy control subjects were used to probe microarrays. Unsupervised hierarchical clustering was used to identify clusters of reactivity, and after unblinding, significance analysis of microarrays was used to identify disease-specific autoantibodies. A bead-based assay was used to validate protein microarray results. Blocking activity of serum containing ACAAs was measured in vitro.

resultsProtein microarrays were highly sensitive and specific for the detection of ACAAs in patients with autoimmune polyendocrine syndrome type I and pulmonary alveolar proteinosis, detecting ACAA levels consistent with those reported in the published literature. Protein microarray results were validated by using an independent bead-based assay. To confirm the functional significance of these ACAAs, we tested and confirmed the blocking activity of select ACAAs in vitro.

conclusionProtein microarrays are a powerful tool for ACAA detection and discovery, and they hold promise as a diagnostic for the evaluation and monitoring of clinical immunodeficiency.

Indexed as

AutoantibodiesCytokinesHumansImmunologic Deficiency SyndromesProtein Array AnalysisAutoantibodiesCytokinesAnti-cytokine autoantibodiesautoimmune polyendocrine syndrome type Iimmunodeficiencyprotein microarraypulmonary alveolar proteinosisthymoma

Identifiers

PMID26365387
PMCPMC4715746
OpenAlexW1638628108

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.